DMEMEDS shared post via Reuters: Atox Bio raises $23 million to fund flesh-eating bacteria treatment

TEL AVIV (Reuters) - Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture capital fund of GlaxoSmithKline. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/RY5dwBzJYeE/story01.htm

Read More